AI to leverage data and close the loop between patient data and R&D
Posted 15th October 2020 by Nicholas Noakes
Ahead of the Global Pharma R&D AI, Data Science and Informatics Summit we sat down with Claire Biot to talk about her work to provide life science companies & professionals with a scientific and business platform to imagine sustainable innovations, capable of improving patient & physician experience in the age of precision medicine.
Computational pathology: Heading for personalised medicine
Posted 3rd June 2020 by Liv Sewell
Computational pathology has increased applications for diagnosis, prediction of prognosis and therapy response, facilitating the movement of healthcare towards personalised medicine.
Coupled with deep learning, such tools are ever more efficient and robust within research and clinical settings.
Speaker profile: Jari Louhelainen
Posted 16th January 2019 by Jane Williams
With many years experience in both cancer research and forensics, we spoke to Associate Professor of Biochemistry Jari Louhelainen about his career so far and what he thinks the future holds for molecular biology.
The future of Organ-On-A-Chip
Posted 9th January 2019 by Jane Williams
Bas Trietsch is the CTO and co-founder of MIMETAS and co-inventor of the OrganoPlate. As CTO he currently drives the continued product development of the OrganoPlate and its peripheral equipment.
Here, Bas talks about what the future holds for organ-on-a-chip and other breakthroughs technologies in biology.
Precision Medicine: Molecular Phenotyping, Diagnostic Development & Patient Subpopulations
Posted 17th December 2018 by Jane Williams
As industry developments continue to improve, the potential for personalised medicine and the possibility of individual diagnosis is on the horizon. These slides, from the Precision Medicine & Biomarkers Leaders Summit: Europe are now available from Andres Hurtado-Lorenzo, Thorsten Gutjahr & Thomas Skot Jensen.
Nicole Pamme on Paper Microfluidics
Posted 9th March 2018 by Jane Williams
At the 3rd Microfluidics Congress: Europe, Nicole Pamme told us about her greatest career achievements and her advice for women in science.
Cancer Therapy in the Genomic Era: Barriers and Distractions
Posted 20th November 2017 by Jane Williams
Recent step change advances in sequencing technologies have delivered a near-complete lexicon of genomic cancer drivers. In parallel, progress in synthetic chemistry has facilitated the assembly of a broad armamentarium of molecularly-targeted therapies. However, whilst immunotherapy agents have produced notable benefits for subgroups of patients, the impact of molecularly-targeted therapies have been relatively modest.
Further unlocking the undeniable power of genomics in cancer will involve both the systematic removal of barriers and the avoidance of distractions that obscure progress. Both of which are discussed here.